$2.65
NASDAQ:
RENB
-0.14 ( -5.02% )
Pricing delayed by 20 minutes
Last updated: 28/03/2024 16:00 EST
RENOVARO CUBE
Renovaro Cube is commited to the early detection of cancer, to intervene at a stage where treatment can be most effective. We are pioneering a multi-modal approach for the early detection of cancer and its recurrence involving blood biopsies, imaging and multi-omics analysis.
For more information on Renovaro Cube, go to their website at www.renovarocube.com.
RENOVARO BIO
Renovaro Biosciences, Inc. has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases.
For more information on Renovaro Biosciences, go to their website at www.renovarobio.com
News Items
February 14, 2024
Statement of Renovaro Inc
We felt compelled to comment on the shorter Hindenburg’s opinion piece.
February 13, 2024
Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.
February 13, 2024
AI Pioneer GEDiCube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine
“We believe this combination marks a significant milestone in the journey of personalized medicine,”
January 25, 2024
Results Shareholders Meeting
All of the matters put forward before the Company’s shareholders for consideration and approval, as set out in the Company’s definitive proxy statement dated January 3, 2024, were approved by the requisite number of votes cast at the meeting.
Information request form
Your inquiries matter. Feel free to use the form below to get in touch, and our team will make it a priority to respond as quickly as possible.